Active, not recruitingPhase 2NCT05211323
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
Studying Carcinoma of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- David HsiehECOG-ACRIN Cancer Research Group
- Intervention
- Atezolizumab(biological)
- Enrollment
- 88 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Palo Alto Medical Foundation-Fremont, Fremont, California, United States
- Memorial Medical Center, Modesto, California, United States
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- Palo Alto Medical Foundation Health Care, Palo Alto, California, United States
- Sutter Roseville Medical Center, Roseville, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- California Pacific Medical Center-Pacific Campus, San Francisco, California, United States
- Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States
- Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States
- Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States
- Carle at The Riverfront, Danville, Illinois, United States
- Carle Physician Group-Effingham, Effingham, Illinois, United States
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05211323 on ClinicalTrials.govOther trials for Carcinoma of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07437859Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor MicroenvironmentPeking Union Medical College Hospital
- RECRUITINGPHASE1NCT07106827A Study of GV20-0251 in Advanced or Refractory Solid TumorsWest China Hospital
- RECRUITINGNCT07466602cfDNA Methylation for Liver Cancer Recurrence DetectionWuhan Ammunition Life-tech Co., Ltd
- RECRUITINGPHASE2NCT07105748HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)Fudan University
- RECRUITINGPHASE2NCT06766643Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver CancerTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT06849180Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal DataZhongda Hospital
- RECRUITINGNANCT06905015Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver ResectionWarangkana Lapisatepun
- RECRUITINGNCT06486454Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)HistoSonics, Inc.
See all trials for Carcinoma of liver and intrahepatic biliary tract →